Global Leading Market Research Publisher QYResearch announces the release of its latest report “Prothrombin Complex Concentrate (PCC) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Prothrombin Complex Concentrate (PCC) market, including market size, share, demand, industry development status, and forecasts for the next few years.
For hematologists, emergency medicine physicians, and hospital formulary managers, the management of bleeding complications in anticoagulated patients presents a critical clinical challenge. The increasing use of oral anticoagulants—warfarin, rivaroxaban, apixaban—among the aging population with atrial fibrillation and venous thromboembolism has created urgent demand for rapid, reliable reversal agents. Traditional approaches such as fresh frozen plasma (FFP) require large infusion volumes, have delayed onset of action, and carry risks of volume overload. Prothrombin Complex Concentrate (PCC) addresses these limitations through a plasma-derived product containing coagulation factors II, VII, IX, and X, offering rapid anticoagulation reversal with lower infusion volumes, faster onset, and reduced volume overload risk. PCC is indicated for congenital and acquired coagulation factor deficiencies, including hemophilia B, factor II/VII/X deficiencies, anticoagulant overdose, vitamin K deficiency, liver disease-related bleeding, disseminated intravascular coagulation (DIC), and coumarin anticoagulant reversal. As clinical guidelines increasingly endorse PCC as the standard of care for urgent anticoagulation reversal, the product has become an essential component of hospital emergency and surgical protocols.
The global market for Prothrombin Complex Concentrate (PCC) was estimated to be worth US$ 1,324 million in 2024 and is forecast to a readjusted size of US$ 2,652 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031. Mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiencies (alone or in combination) including: coagulation factor IX deficiency (hemophilia B), and coagulation factor II, VII, X deficiency overdose of anticoagulants, vitamin K deficiency; patients with hemorrhage caused by liver disease need to correct coagulation dysfunction; when disseminated intravascular coagulation (DIC) occurs, coagulation factors II, VII, IX, and X are consumed in large quantities, which can be used in heparin application after chemotherapy; prothrombin time prolongation due to various reasons and intended for surgery, but may be ineffective for those with coagulation factor V deficiency; treatment of bleeding symptoms in patients with hemophilia A who have produced factor VIII preparations; reversal of coumarin anticoagulant-induced bleeding. In 2024, global Prothrombin Complex Concentrate (PCC) production reached approximately 4.73 million units, with an average global market price of around US$ 280 per unit. The average gross profit margin of this product is 80%.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5445099/prothrombin-complex-concentrate–pcc
Market Segmentation and Competitive Landscape
The Prothrombin Complex Concentrate (PCC) market is segmented as below, featuring a competitive landscape dominated by global plasma fractionation leaders with established collection networks:
Global Leaders:
- CSL Behring: A global leader in plasma-derived therapies, offering comprehensive PCC products across international markets.
- Grifols: A Spanish plasma fractionation leader with strong presence in North American and European markets.
- Octapharma: A Swiss plasma product manufacturer with extensive PCC offerings.
- Takeda: A global biopharmaceutical company with significant plasma-derived product portfolio, including PCC.
- Prothya Biosolutions: A European plasma fractionation company.
- RAAS: A Chinese plasma product manufacturer serving domestic and regional markets.
- Hualan Bio, BOHUI, NUOYI BIO, SINOPHARM, Guangdong Weilun, Weiguang Bio, Kangbo Bio, Huarun Boya, Taibang Biologic: Chinese plasma product manufacturers expanding domestic PCC production capacity.
Segment by Type: Dosage Strengths
100 IU / 200 IU / 300 IU / 400 IU / 1000 IU
PCC products are available in multiple dosage strengths to accommodate:
- Pediatric patients: Lower doses for weight-based dosing in children
- Anticoagulant reversal: Variable dosing based on INR levels and patient weight
- Hemophilia B management: Factor IX replacement dosing
- Surgical prophylaxis: Pre-operative correction of coagulation deficits
- Key characteristics: Weight-based dosing, flexible administration, multiple strengths available
Segment by Application: Clinical Indications
Hemophilia B
Hemophilia B (factor IX deficiency) represents a core indication:
- Congenital deficiency: Genetic disorder requiring factor IX replacement
- Prophylaxis: Regular dosing to prevent bleeding episodes
- On-demand therapy: Treatment of acute bleeding events
- Surgical coverage: Perioperative factor replacement
- Key requirements: Factor IX potency, viral safety, consistent quality
Acquired Coagulation Factor Deficiency
Acquired deficiencies represent the fastest-growing segment:
- Anticoagulant reversal: Warfarin, rivaroxaban, apixaban reversal in bleeding emergencies
- Vitamin K deficiency: Correction of coagulopathy in malnourished patients
- Liver disease: Management of coagulopathy in hepatic dysfunction
- Disseminated intravascular coagulation (DIC): Factor replacement following heparin therapy
- Trauma and surgery: Immediate hemostasis in major bleeding
- Key requirements: Rapid onset, low volume, predictable reversal
Industry Development Characteristics and Market Trends
Market Drivers
The PCC market is driven by several key forces:
- Anticoagulant use expansion: Increasing prescription of warfarin, rivaroxaban, and apixaban in aging populations with atrial fibrillation and venous thromboembolism
- Clinical preference: Superiority over fresh frozen plasma (FFP)—lower infusion volumes, faster onset, reduced volume overload risk
- Trauma and surgical demand: Growing need for immediate hemostasis in emergency departments and operating rooms
- Hemophilia management: Continued need for factor IX replacement in hemophilia B patients
- Technological advances: Viral inactivation and plasma fractionation technologies improving product safety and purity
Market Challenges and Risks
The PCC market faces several constraints:
- Plasma supply limitations: Limited and costly human plasma supply; stringent regulations on plasma collection and cross-border circulation
- Thrombosis risk: Concerns regarding thrombotic complications with repeated or high-dose use
- Competition: Lower-cost alternatives (FFP) preferred in some regions; emerging recombinant hemostatic agents (recombinant Factor VIIa, four-factor recombinant PCC)
- Regulatory barriers: Long approval timelines and strict safety monitoring requirements
- Production constraints: Complex fractionation processes limiting manufacturing capacity
Clinical Application Expansion
PCC demand is expanding beyond traditional indications:
- Emergency departments: Primary end users in Western markets
- Trauma centers: Growing adoption in emerging economies
- Liver disease management: Coagulation disorders in hepatic dysfunction
- Obstetric hemorrhage: Management of postpartum bleeding
- Cardiac and neurosurgery: Intraoperative bleeding management
- Guideline evolution: Increasing standardization in clinical protocols
Supply Chain Dynamics
Upstream supply chain relies on high-quality human plasma:
- Plasma sources: Concentrated in North America and Europe; Asia and Latin America expanding capacity
- Critical factors: Collection volume, viral screening, cold-chain logistics, fractionation technology
- Manufacturer investment: Major players expanding collection networks and localizing supply chains
- Technology advances: Viral inactivation reagents, centrifugation systems, purification resins improving yield
- Supply constraints: Highly regulated, ethically sensitive plasma sourcing remains critical constraint
Geographic Market Dynamics
- North America: Largest market with established plasma collection infrastructure, high anticoagulant use, and strong hospital adoption
- Europe: Mature market with comprehensive plasma fractionation capacity and clinical guideline adoption
- Asia-Pacific: Fastest-growing region; expanding plasma collection capacity, increasing healthcare investment, growing awareness
- Latin America and Middle East: Emerging markets with developing plasma infrastructure
Exclusive Observation: The Convergence of Plasma Collection, Clinical Guidelines, and Anticoagulant Management
Drawing on our ongoing analysis of plasma-derived therapeutics, we observe a significant strategic evolution: prothrombin complex concentrate is increasingly positioned at the convergence of plasma supply security, evolving clinical guidelines, and the expanding anticoagulated patient population. This convergence encompasses:
- Supply chain localization: Manufacturers investing in regional plasma collection to ensure supply security
- Guideline standardization: Incorporation of PCC into anticoagulation reversal guidelines across major clinical societies
- Product innovation: Development of room-temperature stable and ready-to-use liquid formulations
- Recombinant alternatives: Competition from and potential synergies with recombinant factor products
- Emergency preparedness: Stockpiling strategies for mass casualty events and anticoagulant emergencies
For healthcare systems and pharmaceutical companies, this evolution creates opportunities for strategic supply chain development and expanded clinical applications.
Strategic Implications for Stakeholders
For hospital formulary managers and emergency physicians: PCC offers rapid, effective anticoagulation reversal. Key considerations include:
- Protocol development: Establishing PCC as standard of care for anticoagulant reversal
- Inventory management: Maintaining adequate stock for emergency use
- Clinical guidelines: Aligning with updated treatment protocols
- Cost-effectiveness: Evaluating PCC versus FFP in clinical and economic terms
For investors: The 10.4% CAGR reflects exceptional growth with characteristics including:
- Secular demand: Expanding anticoagulant use in aging populations
- Guideline tailwinds: Increasing clinical preference for PCC
- Emerging market growth: Healthcare infrastructure development in Asia-Pacific
- High margins: 80% gross profit margins reflecting product value
For plasma fractionation companies: Success factors include:
- Plasma collection networks: Ensuring reliable, high-quality plasma supply
- Fractionation efficiency: Maximizing yield from plasma resources
- Regulatory expertise: Navigating global plasma product regulations
- Innovation pipeline: Developing next-generation formulations and recombinant alternatives
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
